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E-mail address: stastna@iach.cz (M. Stastna).Stem cell-based therapy is emerging as a novel approach for myocardial repair over conventional
cardiovascular therapies. In addition to embryonic stem cells and adult stem cells from noncardiac
sources, there is a small population of resident stem cells in the heart from which new cardiac cells
(myocytes, vascular endothelial cells and smooth muscle cells) can be derived and used for cardiac
repair in case of heart injury. It has been proposed that the clinical beneﬁt of stem cells may arise
from secreted proteins that mediate regeneration in a paracrine/autocrine manner. To be able to
track the regulatory pathway on a molecular basis, utilization of proteomics in stem cell research
is essential. Proteomics offers a tool that can address questions regarding stem cell response to dis-
ease/injury.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Embryonic stem cells (ESCs) are deﬁned as unspecialized cells
with the capability of dividing and renewing for indeﬁnite periods
but under certain physiologic and experimental conditions, they
can be induced to become speciﬁc cell types performing special-
ized functions, e.g. beating cells of the heart muscle, oxygen-carry-
ing red blood cells, or electrochemical signaling nerve cells.
Although animal and human ESCs have indisputable potential in
cell-based therapy after injury and/or in disease treatment (e.g.
diabetes, Parkinson’s disease, spinal cord injury, heart diseases,
etc.) [1–6], there are several limitations in their clinical applica-
tions. In addition to ethical limitations involved in ESC research,
they have a high proliferation capacity leading to the formation
of teratomas and they can be rejected by the immune system. Thus,
the identiﬁcation of adult stem cells (ASCs), also called progenitor
cells, in many more tissue types than was originally thought, has
led to increased scientiﬁc effort and enthusiasm in stem cell and
clinical research.
Adult mammalian heart has a special need for regenerative
therapy as it has a very limited ability for endogenous renewal,
and events such as heart attack or myocardial infarction (MI) result
in destruction of the complex cardiac architecture and replacement
of myocardium by scar tissue resulting in increased risk of deathchemical Societies. Published by E
tical Chemistry of the ASCR,
20 541 212 113.due to heart failure (HF) or arrhythmia. There is currently no effec-
tive therapy to replace dead/damaged myocardium except cardiac
transplantation. And thus, stem cell-based therapy with stem/pro-
genitor cells offers the promise of organ repair on demand, and ap-
pears to have an immense potential in the treatment of MI and HF.
The discovery of cardiac stem/progenitor cells (CSCs), a small frac-
tion of the total cells residing in the heart, opened the possibility
for autologous heart repair. And thus, efﬁcient methods for their
isolation and expansion to sufﬁcient quantities for therapeutic pur-
poses have been searched and tested, as well as methods for
enhancing the activation of endogenous stem cells or converting
other cells within the heart into cardiac stem cells. There is grow-
ing evidence that proteins secreted from stem/progenitor cells into
the vicinity of the injury can modulate the infarct microenviron-
ment and play an important role in functional improvement
[7,8]. Proteomics, an approach for the study of proteins and their
functions in complex biological systems, is a suitable strategy to
obtain new, and otherwise unavailable, information about stem
cells. By using proteomics we could better understand the mecha-
nisms driving ASC engraftment and differentiation into cardiac
myocytes and vascular cells. This involves understanding the auto-
crine and paracrine manners of proteins secreted by stem/progen-
itor cells, and clarifying how the cell-surface receptors and
signaling proteins stimulate and inﬂuence the differentiation
process.
This minireview focuses on ASCs, with a special emphasis on
CSCs and their potential therapeutic use in heart disease, and on
the role of proteomics in stem cell/cardiac stem cell research.lsevier B.V. All rights reserved.
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Bone marrow ASCs have been used in clinical applications for
years, but ASCs were discovered only recently in other tissues
including brain, blood vessels, liver, and skin. ASCs are undifferen-
tiated cells that reside, in extremely low numbers, among differen-
tiated cells in a mature organ or tissue [9,10]. Unlike ESCs, which
are known to originate in the inner cell mass of blastocyst, the ori-
gin of ASCs in mature tissue is highly speculative with many unan-
swered questions such as: what stopped them from differentiating,
why they are still stem cells when most cells have differentiated? A
recent hypothesis [11] suggests that ASCs arise from the neural
crest, a group of embryonic cells found in the ectoderm during em-
bryo development due to their ability to migrate to numerous loca-
tions in the body and differentiate into various cell types. ASCs can
regenerate and under proper but yet to be fully deﬁned internal/
external stimuli, they can either differentiate into the speciﬁc tis-
sue of their origin or transdifferentiate into multiple cell types.
Transdifferentiation, or plasticity, was reported for e.g. brain stem
cells and bone marrow-derived stem cells [9,12,13]. Bone marrow
hematopoietic stem cells have been shown to transdifferentiate
into brain cells (neurons, oligodendrocytes and astrocytes), liver
cells, and skeletal muscle cells [9,12], while bone marrow stromal
cells (mesenchymal stem cells) may transdifferentiate into skeletal
muscle cells and cardiac muscle cells [13]. Although the articles
claiming little or no evidence for transdifferentiation of adult
hematopoietic stem cells have been published [14–16], the ﬁrst re-
ports of successful transdifferentiation of adult hematopoietic
stem cells into cardiac cells appeared in 2001 [10,13,17]. In these
reports, adult hematopoietic cells were injected directly into dam-
aged myocardium [13] or their enriched forms were transplanted
into bone marrow with subsequent delivery to the heart [10].
When hematopoietic stem cells were injected directly into the
damaged wall of the ventricle of infarcted adult mouse myocar-
dium they were able to generate all three major heart cell lineages,
cardiomyocytes, smooth muscle cells (SMCs), and vascular endo-
thelial cells [13] based on cell-speciﬁc marker expression (cardiac
myosin, factor VIII and a-smooth muscle actin). However, the suc-
cess rate with this invasive approach was only 40% (repair was suc-
cessful in 12 out of 30 mice). The same research group [17] went on
to improve efﬁciency by administration of cytokines (stem cell fac-
tor, SCF, and granulocyte-colony-stimulating factor, G-CSF; in-
jected s.c.), resulting in increased levels and mobilization of adult
bone marrow stem cells into circulation with subsequent translo-
cation to the infarcted portion of the myocardium. The volume of
tissue repair in regenerating myocardium was measured in three
sections and determined as the product of section thickness and
the area occupied by restored tissue. Cardiac repair was character-
ized by a band of newly formed myocardium occupying most of
the damaged area. In the absence of cytokines, myocardial replace-
ment was never observed. This noninvasive cytokine-mediated
autologous therapeutic strategy resulted in a signiﬁcant degree of
tissue regeneration 27 days later, with 73% of mice surviving. In
the latter study [10], highly enriched hematopoietic stem cells
(side population cells) from a genetically altered mouse strain
were transplanted into the bone marrow of a lethally irradiated
mouse subsequently subjected to heart attack. As in [13], hemato-
poietic stem cells were able to engraft and transdifferentiate into
cardiac myocytes and vascular endothelial cells. In a recent study
[18], four types of ASCs in a murine model of myocardial ischemia
were compared: bone marrow mononuclear cells (MNCs), mesen-
chymal stem cells (MSCs), skeletal myoblasts (SkMb), and ﬁbro-
blasts. It was demonstrated that although each cell type has its
own advantages and limitations, there is a clear survival and amodest functional beneﬁt of MNCs in the infarcted mouse heart
resulting in more robust preservation of cardiac function compared
to SkMb and MSCs. There was, however, no evidence of transdiffer-
entiation by donor MNCs into cardiomyocytes.
In addition to murine stem cells, human ASCs from various
sources were shown to transdifferentiate into cardiac cells as well,
either in vitro or when injected into murine hearts, e.g. human
peripheral blood-derived adult stem cells (CD34+, endothelial pro-
genitor cells (EPCs), smooth muscle progenitor cells) [19–21] and
human MSCs [22]. And thus, a large number of studies have been
performed in small animal models (mice/rats) using both foreign
ASCs and pretreated autologous ASCs of various cell types, either
injected directly into infarcted area or transplanted/stimulated in
other body locations with subsequently induced translocation/
mobilization to damaged parts of the myocardium, or injected
intracoronarily or intravenously. Despite considerable experimen-
tal data with rodents, data from large animal studies have been
limited and contradictory. In rabbits, injection of human MSCs into
infarcted region has shown their transdifferentiation into cardio-
myocytes, regeneration of vascular structures, and functional
improvement [23]. Improvement was also observed in a canine
model, in which cardiomyogenic growth factor-pretreated bone
marrow MSCs had a beneﬁcial effect on functional regeneration
of chronically infarcted myocardium [24]. In a porcine model,
intravenous delivery of autologous, allogeneic porcine and human
MSCs resulted in improved myocardial function for all three types
of cell used. However, formation of a non-malignant cardiac tumor
containing mesenchymal tissue was observed in one animal trea-
ted with human MSCs [25]. Another instance of human MSC trans-
plantation improving cardiac function in swine was reported [26],
with markedly greater improvement achieved by cotransplanta-
tion of human MSCs and human fetal cardiomyocytes (1:1) [26].
On the other hand, intracoronary delivery of umbilical cord blood
ASCs, after induced MI in swine, did not show any improvement
in left ventricular function [27], and although intracoronary injec-
tion of unselected bone marrow ASCs and MNCs reduced an infarct
size, surprisingly, there was little or no functional improvement
demonstrated [28]. Initial human clinical results and their out-
comes were recently summarized [29]. Most of the transplanta-
tions have been carried out using unselected bone marrow and
blood-derived progenitor cells in patients with MI or in patients
with chronic HF due to previous MI. The individual trials of the pa-
tient with MI included groups of 10, 59, 60 and 20 patients at 8, 4.9,
4.8 and 13.5 days after MI, respectively. In chronic HF, groups of 8,
10, and 14 patients were examinated, mostly 5–6 years after MI.
Collectively, these human studies have shown the relative efﬁcacy
of intracoronary progenitor cell transplantation for patient with
MI. In chronic ischemic HF treatment, additional questions arose:
e.g. whether identifying hibernating myocardium to direct cell
therapy is essential to an effective outcome, and whether delivery
of skeletal myoblasts to established scar tissue late in the disease
improves clinical outcome once patients are protected against po-
tential arrhythmias by an implantable deﬁbrillator [29]. Safety tri-
als in humans [30–33] have conﬁrmed, at least under experimental
conditions used, that stem cell-based therapy can be relatively safe
and does not at this time appear to be associated with an increase
in the number of adverse clinical events [34]. Still, optimization of
patient cohort, cell processing methods, cell delivery methods, and
cell sources remained to be optimized.
Over time, reviews regarding differentiation of the various ASCs
used for cardiac regeneration have been published [35–39], but
some questions are still unanswered, e.g. whether cardiomyocytes
reported as arising through transdifferentiation could in fact be the
result of cell–cell fusion. Thus, some authors have reported
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cell fusion, based, e.g. on a hybrid genotype displayed by fused
cells [41–43]. According to [44], intrinsic features of stem cells
(clonogenicity, self-renewal and multipotentiality) exclude cell fu-
sion as a necessary requirement for growth and differentiation and
point to the plasticity of stem cells. Still, the cell fusion theory re-
mained as an alternative hypothesis for the concept of stem cell
plasticity [40].3. Cardiac stem/progenitor cells
The heart was for a long time considered a terminally differen-
tiated organ: it was believed that cardiac myocytes could not self-
regenerate after damage and that the only response to injury was
hypertrophy of remaining viable cardiomyocytes resulting in an in-
crease in cardiac mass. The ﬁrst report that ventricular myocytes
are not terminally differentiated in adult heart appeared in 1998
[45]. Moreover, the discovery of stem/progenitor cells residing in
the adult normal or diseased heart which can undergo mitosis,
especially in connection to various types of cardiac damage, and
from which new cardiomyocytes can arise, opened the possibility
for autologous heart cell repair. Although transplantation of fetal
cardiac cells as an optimal cell source into damaged myocardium
displayed promising results in functional improvement [46], simi-
larly to ESCs, ethical and immunological issues, and limited quan-
tity and availability, made application in large-scale clinical trials
impossible. On the other hand, CSCs could offer many advantages
for regenerative therapy, since they are autologous if harvested
and grown in vitro prior to transplantation in the patient, and thus,
immunological complications and disease transmittal are therefore
improbable. CSCs also appear to be more cardiogenic than other
ASCs, and trigger robust angiogenic responses after myocardial
transplantation [47].
The ﬁrst reports of CSCs residing in very low numbers in the
heart appeared in 2003 [41,48,49]. Although controversial [49], it
supported an older observation [50], and showed that increased
cardiac mass resulted from a combination of myocyte hypertrophy
and hyperplasia in human aortic stenosis and that new myocytes
were formed by the differentiation of stem-like cells that ex-
pressed stem cell markers (c-kit, stem cell antigen Sca-1, and
MDR-1) and telomerase, and that their numbers increased more
than 13-fold [49]. The discovery of cell clusters with CSCs making
the transition to cardiogenic and myocyte precursors, and very
primitive myocytes that turned into terminally differentiated myo-
cytes, provided a link between CSCs and myocyte differentiation,
and thus supported the existence of CSCs that amplify and commit
to the myocyte lineage in response to increased cardiac workload
[49]. CSCs have now been shown to differentiate into all types of
cardiac lineages [48,51] and they are self-renewing, clonogenic
and multipotent. To date, they have been identiﬁed in mouse/rat
[48,51], dog [52], pig [53] and human [49,51,53,54] hearts. Re-
cently, several methods for CSC isolation have been developed
[41,48,51,53–55]. The ﬁrst successful isolation of adult CSCs was
reported by Messina et al. [51]. In this study, undifferentiated cells,
growing either from explants of postnatal atrial/ventricular human
biopsy specimens or from murine heart tissues, were able to form
multicellular clusters (cardiospheres, CSps) in suspension culture.
CSps were created by heterogenous population of cells (cardiac
stem cells, differentiating progenitors, spontaneously differenti-
ated cardiomyocytes and vascular cells) and expressed stem cell
and EPC antigens/markers. Murine CSps started beating spontane-
ously after their generation and maintained this function during
their lifespan, whereas human CSps did so only when cocultured
with rat cardiomyocytes [51]. This was recently overcome by
inducing human cardiomyocyte progenitor cells to differentiateinto cardiomyocytes and then form spontaneously beating aggre-
gates in vitro by stimulation with 5-azacytidine, without a need
for coculture with neonatal myocytes [55]. The original culture
method [51] was further modiﬁed to improve efﬁciency, and the
addition of a postcardiosphere expansion step allows one to obtain
reasonable number of cells for transplantation from the small spec-
imen (biopsy) in a timely manner [53]. It is now possible to rou-
tinely replate CSps to yield a monolayer of cardiosphere-derived
cells (CDCs). CSps and CDCs, derived from human biopsy speci-
mens and from comparable porcine samples, expressed antigenic
characteristics of stem cells at each stage of processing, as well
as proteins vital for cardiac contractile and electrical function
[53]. Importantly, human CDCs injected into the border zones of
myocardial infarcts promoted cardiac regeneration and improved
heart function in a mouse infarct model [53]. In another study,
the conditions were established for isolation and expansion of c-
kit-positive human CSCs from small samples of myocardium [54].
Two methodologies for preparation of c-kit-positive human CSCs
were used [54], either an enzymatic dissociation of myocardial
samples, from which c-kit-positive cells were sorted with immun-
obeads and plated at low density to obtain multicellular clones
from single founder cells (successful isolation in 8 of 12 cases) or
a primary explant technique (successful cell outgrowth in 46 of
70 cases). Human CSCs differentiated predominantly into cardio-
myocytes, and to a lesser extent into SMCs and endothelial cells
based on speciﬁc protein expression. For example, human CSCs
generate myocytes positive for cardiac myosin heavy chain, a-sar-
comeric actin, and a-cardiac actinin. In addition, when locally in-
jected in the infarcted myocardium of mice/rats, human CSCs
created a chimeric heart in which human myocardium was struc-
turally and functionally integrated with the rodent myocardium
and contributed to the performance of the infarcted heart. Differ-
entiated human cardiac cells possessed only one set of human
sex chromosomes, indicating that human CSCs form human myo-
cardium independently of cell fusion [54]. Taken together, the pos-
sibility of human CSCs isolated and expanded in vitro with
subsequent autologous application for regeneration of myocar-
dium in patients suffering from HF, appeared to be feasible.
In an interesting paper, hepatocyte growth factor (HGF) and
insulin-like growth factor 1 (IGF-1) were injected intramyocardial-
ly after induced MI in a canine model to stimulate resident CSCs.
This intervention led to the formation of myocytes and coronary
vessels within the infarct, and thus to improvement of cardiac
function [52], and further supported the thesis, that secreted pro-
teins are important and may affect the viability of cells. HGF and
IGF-1 were also used to stimulate c-kit-positive cardiac progenitor
cells in vitro prior to their injection into infarcted myocardium of
rats [56]. In this case, cardiac progenitor cells divided and differen-
tiated into endothelial and SMCs and, to a lesser extent, into
cardiomyocytes that appeared to be mediated by the up-regulation
of hypoxia-inducible factor 1a, which promoted the synthesis and
secretion of stromal-derived factor 1 (SDF-1) from hypoxic coro-
nary vessels [56].
Recently, many of the issues involved in cardiac stem cell-based
therapy have been addressed: some are mentioned above. They in-
clude the establishment of methods for CSC isolation, their pre-
treatment, culturing, and expansion in vitro, various methods for
their delivery to the heart and controlling their growth and matu-
ration afterwards. Even a successful method for stimulation and
activation of the CSC pool in vivo, leading to progressive improve-
ment in cardiac function, was also reported [52]. Although all of
these advancements undoubtedly indicate a big step forward in
cardiovascular disease prevention and treatments, due to their rel-
atively recent discovery, there is an absence of knowledge about
long-term outcomes, possible risks involved, and clinical follow-
up data before a routine therapeutic CSC use. And so, the
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needs to go hand-in-hand with progress in CSC and stem cell-based
therapies. Currently, the methods frequently used, e.g. histologic
analysis (postmortem) and echocardiography, are limited and
insufﬁcient. Direct repetitive visualization of stem cell-based ther-
apy progress in vivo by noninvasive techniques, in terms of identi-
ﬁcation of therapy cell location, magnitude and length of survival,
is still a big challenge. And thus, to address this issue, novel prom-
ising methods like magnetic resonance imaging (MRI), nuclear
imaging, reporter gene imaging and quantum dot imaging are
emerging and further improved for application to stem cells [57]
Proteomics, the method for identiﬁcation and quantiﬁcation of
proteins, can help to clarify the molecular basis of stem cell re-
sponse to injury: mechanisms leading to stem cell differentiation
and maturation and the role of proteins secreted by stem cells in
the regenerative process.4. The role for proteomics in stem cell research
Proteomics is a scientiﬁc discipline in which analytical protein
biochemistry is applied in a manner that allows simultaneous
assessment and characterization of many proteins. This involves
quantiﬁcation of proteins, and the ability to distinguish among
the protein isoforms arising from mRNA splice variants or genes.
As well, proteomics can characterize the proteins and determine
posttranslational modiﬁcation (PTM) status, including phosphory-
lation, glycosylation, etc. Proteins are the actual mediators of most
cell mechanisms and processes. Proteomics, a method for study of
proteins and their functions in complex biological systems, can ex-
tend, be complimentary to other scientiﬁc approaches and more-
over, provide new information about stem cells that would
otherwise be unavailable.
The majority of stem cell proteomic studies have relied on two
dimensional gel electrophoresis (2-DE), which separates proteins
according to pI (charge) and mass (molecular weight), and on mass
spectrometry (MS) for protein identiﬁcations. 2-DE is particularly
well suited for identiﬁcation of PTMs with pI shifts observed in
gels, and for providing the quantitative data. Although widely used,
2-DE does have however several limitations, e.g. solubilization of
hydrophobic membrane proteins is problematic, and the identiﬁ-
cation of low abundant proteins can be difﬁcult. Thus, different
strategies have been developed to increase the protein solubility,
based mostly on detergents or various combinations of chaotropes.
To increase detectability of low abundant proteins, intensive pre-
fractionation of complex sample mixture can be used prior to
detection and different methods for enrichment/isolation/afﬁnity
puriﬁcation of subgroups of proteins of interest can be applied.
This can be from isolation of a particular organelle or to identify
protein chemical property such as pI or PTM. Mass spectrometers
are ultimately used to identify proteins, either single MS instru-
ments such as matrix-assisted laser desorption/ionization-time of
ﬂight (MALDI-TOF) for peptide mapping (peptide mass ﬁngerprint-
ing) or tandem instruments like MALDI-TOF-TOF or one of many
LC–MS/MS instruments which further fragment peptides in order
to obtain the amino acid sequences. For quantitative comparison
of multiple samples, MS techniques using protein/peptide labeling
such as iTRAQ (isobaric tags for relative and absolute quantiﬁca-
tion) or SILAC (stable isotope labeling by amino acids in cell cul-
ture) can be used or even label-free techniques are feasible on
high accuracy MS instruments. However, for absolute quantiﬁca-
tion, spiked in standards must be used, and analysis is often carried
out with multiple reaction monitoring (MRM) in a triple quadru-
pole/linear ion trap MS instrument.
Modern MS instruments and techniques allow identiﬁcation of
proteins in femtomole to picomole range. Other gel-free separationtechniques can be used in proteomics, either alone or in various
combinations prior to MS detection in multidimensional arrange-
ment (mostly various modes of liquid chromatography). Recently,
new techniques have been developed and used for stem cell anal-
ysis [58,59]. For example, one approach addressed the problem of
identiﬁcation of proteins occurring in low abundance, in which no-
vel MS-based proteomic method called iterative exclusion (IE-MS)
was successfully applied for identiﬁcation of previously undetect-
able growth factors in human ESCs present in concentrations of
109–1011 g/mL [58]. In this method, the same sample is run
many times with excluding of peptides already detected and
allowing only new ones to be observed with each subsequent anal-
ysis. Another new technique targeted the difﬁculties associated
with analysis of membrane protein as well as their low presence
in cells [59]. In this study [59], a strategy for membrane protein
proﬁling by using combination of differential in-gel electrophoresis
DIGE technology (CyDye labeling) was described with subsequent
membrane protein enrichment by biotin/avidin puriﬁcation. By
this method they were able to discriminate membrane and mem-
brane-associated proteins from intracellular contaminants and
identify additional markers during mouse ESC differentiation. In
addition to methods aforementioned, numerous proteomic tech-
niques have been developed and improved in recent years to suit
speciﬁc stem cell research needs [60–63]. Many stem cell proteo-
mic studies have been aimed at human stem cells either ESCs or
ASCs [61,62]. They have followed several major directions, as de-
scribed below, and they are depicted schematically in Fig. 1.
4.1. Global protein screening – what makes a stem cell as stem cell
Global protein proﬁling has been performed for various cell
types with further extension to comparative analyses leading to
recognition of cell lineage similarity/diversity either within the
same species or for different species compared. For example, a
characterization of MSCs [64] or neural stem cells from rat [65]
and human [66] was carried out for better understanding of their
physiologies. The global proteome identiﬁcation of murine ESCs
was published recently [67,68]. The latter study revealed more
than 5000 proteins, thus creating the largest stem cell proteome
reported to date [68]. It was shown that ESCs can be SILAC-labeled
when grown feeder-free during the last phase of cell culture. Two
different preparation approaches were compared: cell fraction-
ation followed by 1-DE separation, and in-solution digestion of to-
tal cell lysate combined with isoelectric focusing. Both preparation
methods were then followed by LC–MS/MS protein/peptide identi-
ﬁcation, and resulted in comparable proteome coverage for either
approach used [68].
4.2. Differentiation – what are the initiating and control hubs
Another direction included proteomic monitoring of develop-
mental processes during stem cell differentiation. Protein expres-
sion changes during stem cell differentiation revealed, for
example, a close relationship between mouse ESC-derived cardio-
myocytes and neonatal cardiomyocytes and certain similarities
with original mouse ESCs [69]. Other studies identiﬁed and
mapped the protein expression changes during differentiation of
mouse ESCs into Sca-1+ progenitor cells (which are meant to have
a potential to serve as precursors of vascular SMCs), and performed
further comparisons with the proteome of mouse adult aortic
SMCs. It was found that although SMCs derived from ESCs can ex-
press smooth muscle markers, the proteome is very different from
mature aortic SMCs [70–72]. Heat shock protein Hsp25 was iden-
tiﬁed as useful marker of early ESC differentiation, with a gradual
decrease to levels barely detectable at 4 days following differenti-
ation [73]. Quantitative analysis of the changes in protein expres-
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Fig. 1. Schema outlining opportunities for proteomics to address key questions in stem cell research. 1-DE: one dimensional gel electrophoresis; 2-DE: two dimensional gel
electrophoresis; 1-DLC: one dimensional liquid chromatography (reversed phase); 2-DLC: two dimensional liquid chromatography.
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ferentiation in a cell model of human MSCs, established by overex-
pression of the human telomerase reverse-transcriptase gene,
revealed that expression levels changed by at least 2-fold upon
osteoblast differentiation, with an increase for 83 proteins (e.g.
alkaline phosphatase, versican core protein and tenascin) and a de-
crease for 21 proteins (e.g. fatty acid synthase) [74].
4.3. Stem cell markers and the cell surface
Although stem cell-based regenerative and reparative thera-
pies are currently in preclinical and clinical trials, number of spe-
ciﬁc cell markers is insufﬁcient as well as identiﬁcation of
signaling proteins/cell-surface receptors. The proteins of the plas-
ma membrane are of great importance and interest in stem cell
research. Approximately 20–30% of all genes in many organisms
encode integral membrane proteins [75]. Cell-surface proteins
are involved in basic cellular processes such as signal reception
and transduction, internal/external cell communication, interac-
tion, and transportation. They are targets for therapeutic mole-
cules, and thus the discovery of novel proteins (biomarkers) and
understanding of their functions, will help in both diagnostics
and therapy. Proteomics can provide new valuable information
about cell signaling mechanisms [63,76] and add to the number
of cell-speciﬁc biomarkers already known. Although plasma mem-
brane protein hydrophobicity (less solubility), functional altera-
tions due to PMTs and relatively lower abundance compared to
other cellular proteins make proteomic analysis of the plasma
membrane challenging, new methods are being developed to
overcome these problems. Thus, e.g. subcellular fractionation
methods, employing various centrifugation techniques and/or
chemical labeling/tagging methods for surface protein enrichment
and puriﬁcation have been implemented. In addition to the exam-
ple already mentioned [59], in which DIGE technology combined
with biotin/avidin enrichment allowed identiﬁcation and compar-
ison of membrane proteins of mature and ESC-derived SMCs, pro-
teomic analysis of the hydrophobic fraction of human MSCs from
umbilical cord blood has yielded 32 protein identiﬁcations, of
which 2 proteins were shown to be cell-surface proteins, using
a combination of centrifugation steps, 2-DE and MALDI-TOF MS
analysis [77]. A similar strategy, with centrifugation steps prior
to LC–MS/MS, was used for identiﬁcation of novel membrane pro-
tein markers in a human MSC line undergoing osteoblast differen-tiation [74]. This study identiﬁed 148 integral membrane or
membrane-anchored proteins, 159 membrane-associated pro-
teins, 29 integrins and cell adhesion proteins, and 20 receptors
out of a total of 463 proteins. An enhanced enrichment strategy,
using both cell-surface biotin labeling and discontinuous sucrose
density gradient followed by MS was used for identiﬁcation of
cell-surface markers and signaling molecules in mouse ESCs
[78]. Here, diverse cell-surface proteins were identiﬁed with
receptors, transporters and cell adhesion molecules as the major
identiﬁed protein groups. Since many interesting cell-surface pro-
teins can be glycosylated, a cell-surface capturing technology for
selective detection of stem cell-surface glycoproteins was recently
developed [76], in which less than 15% contamination from intra-
cellular and non-glycosylated peptides/proteins were observed by
MS identiﬁcation. This technique proved to be highly selective for
low abundant plasma membrane proteins, compared to chemical
tagging glycoprotein and high afﬁnity enrichment techniques.
4.4. Secretomes: paracrine/autocrine factors and other proteins
secreted by stem cells
Proteins secreted by cells (secretomes) are important since their
secretions are speciﬁc for each cell type, and reﬂect the local envi-
ronment of the cells (cellular state). It has been documented in
studies on stem cell-based therapies that the correlation between
the numbers of new cells forming at the site of an injury does
not often correspond to the degree of observed functional improve-
ment [53]. And thus, an alternative hypothesis based on paracrine
mechanisms was suggested and frequently discussed at present, in
which paracrine/autocrine mechanisms mediated by either endog-
enous or transplanted exogenous stem cells are meant to contrib-
ute to regeneration and repair process [7,8]. Paracrine and
autocrine factors are deﬁned as proteins synthesized and secreted
by a cell, which can diffuse into the near vicinity and induce
changes in neighboring cells or in the originating cell itself. In some
cases, the autocrine/paracrine protein can affect the originating
cell prior to its secretion. Common paracrine factors can be divided
into several major families, such as ﬁbroblast growth factors,
Hedgehog proteins, Wnt family proteins, and transforming growth
factor TGF-ß superfamily. In addition to the families mentioned,
there are other paracrine factors, e.g. epidermal and HGFs, neuro-
trophins, cytokines, interleukins and various factors that play an
important role during development.
Table 1
Proteomic application in stem cell-based cardiac research.
Ref. Cell source Proteomic method Finding Proteins/# proteins identiﬁed
[69] Mouse ESCs,neonatal
cardiomyocytes
2-DE 95% of proteins matched between ESC-derived
cardiomyocytes and NCs
60
[70] Mouse ESCs 2-DE, MALDI-TOF MS, MS/
MS
Sca-1+ protein database 241
[72] Mouse ESC-derived SMCs,
mouse aortic SMCs
DIGE, MALDI-TOF MS, LC–
MS/MS
Comparative analysis; ESC-derived SMCs express smooth
muscle markers but are different from aortic SMCs
146 protein differed between ESC-
derived SMCs and aortic SMCs
[59] Mouse ESC-derived SMCs,
mouse mature SMCs
DIGE, biotin–avidin labeling Comparative analysis of plasma membrane proteins; ESC-
derived SMCs maintain characteristics of their ESC origin
E-cadherin, integrin alpha6, CD98
(4F2) upregulated in ESC-derived
SMCs
[80] EPCs MALDI-TOF MS, nanoﬂow
liquid chromatography, DIGE
TP found in conditioned medium from EPCs stimulated
endothelial cell migration and promoted angiogenesis
Thymidin phosphorylase (TP)
[81] Murine ESCs DIGE, LC–MS/MS, LTQ-FT
MS, multidimensional LC
TNFa-primed secretome mediated promotion of ESCs to
cardiac commitment
99
[82] Resident CSCs in infarcted
myocardium of mouse
2-DE, MALDI-MS Differentiation of resident CSCs into diversed cardiac cell
types indicated by up-regulation of nestin
26
NCs: neonatal cardiomyocytes; SMCs: smooth muscle cells; EPCs: endothelial progenitor cells; CSCs: cardiac stem cells; TP: thymidine phosphorylase (proangiogenic factor);
FT: Fourier transform.
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response to injury, and it has been suggested that these paracrine
factors can signal and activate resident ASCs or induce mobiliza-
tion and homing of stem cells into damaged tissue from various
locations through the circulation. It was observed that progenitor
cells can improve cardiac function, under experimental conditions,
even with low or absent cardiac differentiation [57]. In cardiovas-
cular research, transplanted exogenous stem cells releasing para-
crine factors can inﬂuence neovascularization, myocardial
protection, cardiac remodeling, and contractility [7]. Nevertheless,
if paracrine mechanisms themselves are sufﬁcient or whether their
combination with stem cell transplantation or other factors are
necessary for satisfactory results, remains an open question. Yet,
identiﬁcation of paracrine factors released by stem cells into sur-
rounding damaged tissue could lead to the possibility to replace
stem cell-based therapy by simple protein-based therapy [7] in
which a ‘‘mixture” of speciﬁc proteins, with proper concentrations
and timing, could be administered to patients.
In [79], microarray experiments were paralleled with proteo-
mics with signiﬁcant release of angiogenic factors, vascular endo-
thelial growth factor VEGF, stromal cell-derived factor-1 SDF-1
and IGF-1 proteins into a cell culture supernatant of EPCs. More-
over, conditioned media from EPCs induced a strong migratory re-
sponse of mature endothelial cells, and signiﬁcantly stimulated the
migration of resident cardiac c-kit+ progenitor cells in vitro [79].
Another proangiogenic factor, thymidine phosphorylase (TP), was
identiﬁed in proteins secreted by EPCs, and its key role in EPC sur-
vival and angiogenesis was conﬁrmed using a combination of RT-
PCR, multiplex cytokine assays, and proteomics [80]. In another
study, cardiogenic priming of the endoderm with tumor necrosis
factor alpha TNFa (a cardiogenic inducer) was investigated by
comparative proteomics. It was found, by using DIGE and MS tech-
niques, that 75% of protein species were increased in TNFa-primed
compared to unprimed endodermal secretome. Protein–protein
interaction analysis revealed a TNFa-centric secretome network
with cardiovascular development as the primary developmental
function. The function of this cardioinductive network was vali-
dated by direct application of the TNFa-primed secretome on ESCs
potentiating cardiac commitment and sarcomerogenesis, whereas
exclusion of TNFa from the network during its generation demoted
the primary ranking of cardiovascular development [81]. Upregu-
lated expression of the intermediate ﬁlament protein nestin in
the infarcted myocardium, as determined by proteomics, was re-
lated to differentiation of resident CSCs into various lineages,
including cardiomyocytes [82]. Intracoronary injection of condi-
tioned media derived from porcine autologous EPCs was associatedwith increased cardiomyocyte size in the infarct territory in condi-
tioned media treated groups as compared to controls. Analysis of
conditioned media detected elevated levels of TGFbeta1, a recog-
nized mediator of hypertrophic signaling in the heart. The hyper-
trophic effect of TGFbeta1 was further conﬁrmed by neutralizing
antibodies/recombinant TGFbeta1 added into conditioned media,
leading to attenuation/restoration of the hypertrophic effect
in vitro [83]. Conditioned media from bone marrow MNCs injected
into acutely infarcted hearts resulted in increased capillary density,
decreased infarct size, and improved cardiac function compared to
controls [84].
The effect of paracrine factors can be increased by genetic mod-
iﬁcation of stem/progenitor cells. It was documented that geneti-
cally modiﬁed stem cells may release therapeutic paracrine
factors and also show better reparative potential compared to con-
trol (untreated) stem cells. For example, MSCs with a hypoxia reg-
ulated heme oxygenase-1 vector injected into infarcted hearts led
to improved stem cell survival compared to control MSCs [85]
and Bcl-2 engineered MSCs inhibited apoptosis, expressed higher
amounts of VEGF, and improved heart function in rats [86]. The
overexpression of the survival protein Akt in MSCs resulted in
secretion of HGF, thymosin-b4, and secreted frizzled-related pro-
tein-2, paracrine factors that inﬂuence myocardial protection, im-
prove cell survival, and decrease cell death [87]. Paracrine factors
secreted from ASCs were extensively listed in [7,8]. Although
published applications of proteomics in stem cell-based cardiovas-
cular research are not numerous, some of them are summarized in
Table 1.5. Conclusion
Stem cells hold great promise in cardiac medicine. Moreover,
resident CSCs even offer a suitable and autologous source for repair
and regeneration. Although methods for their isolation, expansion,
and transplantation have been developed, the best options for opti-
mal results remain to be examined and established. From murine
to larger animal models to human clinical trials, application of
stem cells in cell-based therapy has shown to be relatively safe,
and has resulted in higher efﬁciency results compared to conven-
tional methods used. In addition, based on the paracrine mecha-
nisms of proteins secreted by stem cells, alternative approach of
protein-based therapy was discussed and experimental evidence
obtained recently. Thus, the possibility of efﬁcient, noninvasive
treatments for cardiovascular diseases seems to be even closer.
Although proteomics has not been implemented sufﬁciently in
1806 M. Stastna et al. / FEBS Letters 583 (2009) 1800–1807stem cell studies yet, it has a big potential and can address many
issues and obtain information not accessible by other techniques.
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